Competitive and operating impacts of deregulation of pharmaceutical sales and legal amendments
First written in FY2017. 3 of 7 entries say "Restated". Latest entry: FY2026.
Sugi Holdings moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2021: 1 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Declining profitability due to revisions to drug prices and dispensing fees, and rising compliance costs associated with amendments to the Pharmaceuticals and Medical Devices Act and other laws」
It identifies revisions to drug prices and dispensing fees, amendments to the Pharmaceuticals and Medical Devices Act and other laws, and related compliance costs as regulatory risks. - FY2025RestatedAnnual report
「As countermeasures, we will develop specialized personnel, including pharmacists and registered sales clerks, to provide high-value-added service in stores, and consider new sales channels such as e-commerce.」
It continues to pursue the development of specialized personnel and the consideration of sales channels such as e-commerce as countermeasures against intensifying competition due to regulatory deregulation. - FY2022Countermeasures specifiedAnnual report
「As countermeasures, we will develop specialized personnel, including pharmacists and registered sales clerks, to provide high-value-added service in stores, and consider new sales channels such as e-commerce.」
As countermeasures against the risk of intensifying competition due to regulatory deregulation, it specifies strengthening customer service through the development of specialized personnel and new sales channels such as e-commerce. - FY2021WorsenedAnnual report
「Other regulatory deregulation is also under consideration, including restrictions on the hours during which over-the-counter medicines may be sold and remote-supervised sales by qualified personnel. Progress in deregulating the sale of over-the-counter medicines may intensify competition due to new entrants from other industries, which could affect the performance of the Group.」
In addition to the existing registered sales clerk system and the lifting of the ban on internet sales, the potential deregulation of restrictions on sales hours and remote-supervised sales has been added as a risk factor under consideration. - FY2020RestatedAnnual report
「The introduction of the registered sales clerk system under the revised former Pharmaceutical Affairs Law, effective 1 June 2009, and the effective deregulation of internet sales of over-the-counter medicines under the revised former Pharmaceutical Affairs Law, effective 12 June 2014, may intensify competition due to new entrants from other industries, which could affect the performance of the Group.」
It continues to describe the risk of intensifying competition due to the registered sales clerk system and the lifting of the ban on internet sales of over-the-counter medicines. - FY2018RestatedAnnual report
「The introduction of the registered sales clerk system under the revised former Pharmaceutical Affairs Law, which took effect on 1 June 2009, and the effective deregulation of internet sales of over-the-counter medicines under the revised former Pharmaceutical Affairs Law may intensify competition with companies in other industries, which could affect the performance of the Group.」
It continues to describe the risk of intensifying competition due to the registered sales clerk system and internet sales of over-the-counter medicines. - FY2017First statedAnnual report
「The introduction of the registered sales clerk system under the revised former Pharmaceutical Affairs Law and the effective deregulation of internet sales of over-the-counter medicines may intensify competition with companies in other industries, which could affect the performance of the Group.」
It identifies intensifying competition with companies in other industries due to regulatory deregulation, including the registered sales clerk system and the lifting of the ban on internet sales of over-the-counter medicines, as a risk.